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A B S T R A C T
Objective: To describe the management of prenatal care and delivery in patients bearing 
autoimmune hepatitis associated with moderate or severe thrombocytopenia. 
Methods: This study was performed in a tertiary level university hospital. Thiteen pregnancies 
in ten patients diagnosed with autoimmune hepatitis, complicated by thrombocytopenia, 
were retrospectively analyzed. The inclusion criteria were as follows: clinical diagnosis of 
autoimmune hepatitis, moderate or severe thrombocytopenia (platelet count < 100 x 103/mm3), 
gestational age at birth over 22 weeks, and patient followed-up by a specialized team at the 
institution. The variables studied were: maternal age, parity, treatment regimen, platelet 
count, examinations for investigation of hepatic function, type of delivery, weight at birth, 
and gestational age at the time of delivery.
Results: The average maternal age was 24.5 years (SD = 5.3) and six (50%) occurred in 
nulliparous women. During pregnancy, monotherapy with prednisone was adopted in 
11 cases (92%). According to the autoantibody profiles, seven pregnancies (58%) had the 
autoimmune hepatitis type I diagnosis, two pregnancies had type II (17%), and three 
pregnancies (25%) had cryptogenic chronic hepatitis (undetectable titers of autoantibodies). 
Portal hypertension was featured in 11 pregnancies (92%). The average gestational age 
at delivery was 36.9 weeks (SD = 1.5 weeks), with an average weight at birth of 2,446g 
(SD = 655g). Eight infants (67%) were small for gestational age. At the time of delivery, severe 
thrombocytopenia was featured in four cases (33%) and cesarean surgery was performed 
in seven cases (58%). Complications at delivery occurred in three cases (25%), one patient 
presented uterine atony, and two patients presented perineal bruising. There was no 
perinatal or maternal death.
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Conclusion: The complications of thrombocytopenic patients with autoimmune hepatitis are 
elevated; nevertheless, with appropriate attention and care, they can be resolved. The association 
between two severe pathologies appears to increase the risk of prematurity and fetal growth 
restriction, demanding specialized prenatal care, as well as surveillance of fetal well-being.
Introduction
Autoimmune hepatitis is a chronic inflammatory disease 
that is prevalent in young women, affecting the hepatic 
parenchyma by means of autoantibodies. It presents a variable 
clinical picture from asymptomatic to acute liver failure. In a 
general way, it is characterized by non-specific symptoms such 
as: fatigue, faintness, and discomfort, followed by an increase 
in hepatic enzymes. There is usually an association with other 
autoimmune diseases, and a genetic predisposition has been 
described. In spite of its severity, it presents a good response 
to corticosteroid clinical treatment.1
As autoimmune hepatitis treatment strategies improved, 
pregnancy in such patients increased, especially in patients 
with the disease under control.2 Notwithstanding, few studies 
investigate the results and consequences that the disease and 
its treatment can have on to pregnancy, and the implications 
at the time of delivery.
The present study aims to describe the management 
of prenatal  care and delivery in patients bearing 
autoimmune hepatitis associated with moderate or severe 
thrombocytopenia. Such an investigation is justified since few 
studies have specifically approached this subgroup presenting 
a higher severity. In addition, laboratory evolution, frequency 
of bleeding complications, and the healthcare needed in 
pregnancy, delivery, and puerperium were also evaluated. 
Methods
This study was performed in a tertiary level university 
hospital and covered the period from April, 2001 to July, 2011. 
It was a retrospective and descriptive study, in which data 
were collected from medical records of pregnant women 
diagnosed with autoimmune hepatitis and moderate or sever 
thrombocytopenia. These patients were followed-up by the 
prenatal team specialized in hemopathies and pregnancy 
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Manejo clínico e obstétrico em gestantes portadoras de hepatite autoimune 
complicada pela plaquetopenia moderada ou grave
R E S U M O
Objetivo: O presente trabalho tem como objetivo descrever o manejo do pré-natal e do parto em 
pacientes portadoras de hepatite autoimune associada à plaquetopenia moderada ou grave. 
Métodos: Este trabalho foi realizado em hospital universitário, de nível terciário. Foram analisa-
das, retrospectivamente, 13 gestações em dez pacientes com diagnóstico de hepatite autoimu-
ne complicadas pela plaquetopenia. Os critérios de inclusão foram: diagnóstico clínico de he-
patite autoimune, plaquetopenia moderada ou grave (contagem de plaquetas < 100 x 103/mm3), 
idade gestacional ao nascimento acima de 22 semanas e pacientes acompanhadas por equi-
pe especializada da instituição. As variáveis estudadas incluíram idade materna, paridade, os 
regimes de tratamento, contagem de plaquetas, exames para investigação da função hepática, 
tipo de parto, peso ao nascer e idade gestacional no momento do parto.
Resultados: A média da idade materna foi de 24,5 anos (DP = 5,3) e seis (50%) ocorreram em nu-
líparas. Durante a gravidez, a monoterapia com prednisona foi adotada em 11 (92%) casos. De 
acordo com o perfil de autoanticorpos, sete (58%) gestações possuíam diagnóstico de hepatite 
autoimune tipo I, duas (17%) do tipo II e três (25%) eram portadoras de hepatite crônica crip-
togênica (títulos de autoanticorpos indetectáveis). A hipertensão portal foi caracterizada em 
11 (92%) gestações. A idade gestacional média no parto foi de 36,9 semanas (DP = 1,5 semana), 
com média de peso ao nascer de 2446g (DP = 655g), sendo oito (67%) pequenos para a idade 
gestacional. No momento do parto, a plaquetopenia grave foi caracterizada em quatro (33%) 
casos e a cesárea foi realizada em sete (58%). As complicações no parto ocorreram em três 
casos (25%), uma paciente apresentou atonia uterina e duas, hematoma perineal. Não houve 
morte materna ou perinatal.
Conclusão: As complicações em pacientes plaquetopênicas com hepatite autoimune são elevadas, 
no entanto, com os cuidados e atenção necessários, podem ser contornáveis. A associação de duas 
patologias graves parece aumentar o risco de prematuridade e restrição do crescimento fetal, 
demandando atenção pré-natal especializada, bem como vigilância do bem-estar do concepto.
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
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at this institution. The research was approved by the ethics 
committee in research of this institution (project No. 695/08).
Pregnant women were followed-up from prenatal care 
until the final phase of pregnancy, at the delivery, and 
puerperium. The following inclusion criteria were adopted: 
autoimmune hepatitis diagnosis established previously to 
pregnancy by the presence of auto-antibodies and/or hepatic 
alterations compatible with the disease; presence of moderate 
thrombocytopenia (between 50 and 100x103 platelets/mm3) 
or severe thrombocytopenia (< 50x103 platelets/mm3) during 
the pregnancy; start of prenatal care at least in the second 
gestational trimester; and follow-up until delivery and 
puerperium. 
The determination of the type of autoimmune hepatitis 
was performed based on autoantibodies profile. Patients 
bearing titers of antinuclear antibodies (ANA autoantibodies) 
anti-smooth muscle (ASM) equal to or greater than 1/40 were 
classified as type I; these same titers for ALKM-1antibody 
(kidney and liver microsomal) and ALC-1 (hepatic cytosol) 
characterized autoimmune hepatitis type II.3 When the titers 
of auto-antibodies were undetectable, cryptogenic chronic 
hepatitis was characterized. 
Prenatal care of those patients was initially performed by 
monthly consultations, until the end of the second trimester, 
at which point they became fortnightly; when closer to 
the end of pregnancy, the consultations were performed 
on a weekly basis. At the start of prenatal care, besides 
the usual laboratory tests, examinations for investigating 
hepatic function were requested: alanine transaminase 
(ALT), aspartate aminotransferase (AST), gamma-glutamyl 
transferase (GGT), alkaline phosphatase (AP), direct billirubin 
(DB), and indirect billirubin (IB). The adopted medication was 
based on the treatment in use at the moment in which the 
pregnancy occurred, generally prednisone corticotherapy. 
Clinical or obstetrical complications verified during the 
pregnancy were studied. Hepatic function examinations, 
platelet count, and hemoglobin (Hb) and haematocrit (Ht) 
levels were serially monitored according to the case severity, 
at prenatal care returns, and as needed by alteration of these 
factors, with earlier returns. A coagulogram (activated partial 
thromboplastin time – APTT, prothrombin time – PT, and 
thrombin time – TT) was performed in the third trimester and 
close to the date of delivery. Besides specific autoantibodies 
profile data, the results of hepatic biopsy and/or clinical 
history of portal hypertension and esophageal varices 
were surveyed. During prenatal follow-up, the presence of 
esophageal varices was reviewed through high digestive 
endoscopy, mainly for verifying varicose vein caliber and 
choosing the method of delivery. 
Fetal follow-up during the prenatal care in autoimmune 
hepatitis cases was performed through obstetrical 
ultrasonography for estimating fetal weight and weekly 
vitality exams (tocodynamometry, fetal biophysical 
profile, and amniotic fluid index [AFI]) from the 32nd week 
of pregnancy, which allowed the diagnostic suspicion of 
fetal growth (fetal estimated weight < 10th percentile) and 
changes in the amniotic liquid volume (oligohydramnios was 
characterized when the AFI was lower than or equal to 5.0 cm). 
Delivery (vaginal or cesarean) was scheduled, respecting the 
conventional obstetrical conditions for indicating cesarean 
surgery, such as Iterative cesarean, breech deliveries, 
meconium, impossibility of labor induction by presence of 
previous cesarean surgery, and changes derived from the 
base disease found at the prenatal follow-up, such as large 
caliber esophageal varices. Labor induction was performed 
by intravenous infusion of oxytocin, when there were 
contraindications to its use. When the cervix was unfavorable 
(Bishop’s score lower than five), cervix preparation was 
performed by using misoprostol and later induced with 
oxytocin. Fetal and uterine contraction monitoring by 
cardiotocography was performed during the period of 
delivery. At childbirth, when the pudendum nerve blockade 
was indicated by vaginal delivery, 2% lidocaine was used. The 
following variable factors concerning perinatal results were 
investigated: gestational age at childbirth; occurrence of fetal 
suffering; weight at birth; newborn weight adequacy; Apgar 
scores at the 1st, 5th, and 10th minute; and perinatal mortality.
Table 1 – Maternal features, and clinical and obstetrical 
data from pregnant women with autoimmune hepatitis 
complicated by moderate or severe thrombocytopenia 
(n = 12).
Feature Value
Maternal age, years, average (SD) 24.5 (5.3)
Nulliparous, n (%) 6 (50%)
Types of autoimmune hepatitis, n (%)
Type 1 7 (58%)
Type 2 2 (17%)
Cryptogenic chronic hepatitis 3 (25%)
Esophageal varices, n (%)
Fine caliber or eradicated 7 (58%)
Medium/large caliber 5 (42%)
Gestational age at childbirth, weeks, average (SD) 36.9 (1.5)
Type of delivery, n (%)
Vaginal 5 (42%)
Cesarean 7 (58%)
Delivery complications
Perineal hematoma 2 (17%)
Uterine atony 1 (8%)
Weight at birth, g, average (SD) 2446 (655)
Weight at birth adequacy, n (%)
AGA 3 (25%)
SGA 8 (67%)
LGAG 1 (8%)
Apgar score at 1st min < 7, n (%) 1 (8%)
Apgar score at 5th min < 7, n (%) 0
AGA, adequate for gestational age; SGA, small for gestational age; 
LGA, large for gestational age; SD, standard deviation.
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Table 2 – Description of pregnancies in patients bearing autoimmune hepatitis, complicated by moderate or severe thrombocytopenia (n = 12). 
Case Profile of antibodies Gestation Age
(years)
Obstetrical 
complication
Treatment
(predinisone)
Cirrose 
hepática
Esophageal 
varices
Platelets at 
deliverya 
(thousand/
mm3)
Gestational 
age at delivery 
(weeks)
Type of 
delivery
Weight at birth 
(g)
Postpartum 
complication
1 SMA (kidney) vascular 
1/160 glomerular 1/80 
tubular + and SMA 
(stomach) 1/160
1 20 Urinary infection 60 mg/d + Fine 48 37.4 Vaginal 2,570 Uterine atony
2 26 Premature rupture 
of membranes + 
gestational
diabetes 
20 mg/d + Fine 111 37.6 Vaginal 2,970 -
2 – 1 19 Fetal growth 
restriction
5 mg/d - Absent 78 37.6 Cesarean 2,410 -
3 SMA (kidney) vascular 
+ glomerular + tubular 
and SMA (stomach) 1/40
1 16 - 7,5 mg/d + Fine 88 37.9 Forceps 2,470 -
4 ALKM -1 
(kidney) > 1/320 
and ALKM-1 
(stomach) > 1/320
1 24 - 20 mg/d - Average 47 38.4 Cesarean 4,120 -
5 SMA (kidney) vascular 
1/40 glomerular 
-tubular - and SMA 
(stomach) 1/40
1 33 - No + Large 77 38 Cesarean 2,500 -
6 SMA (kidney) vascular 
> 1/320 glomerular 
1/320 tubular + and 
SMA (stomach) >1/320
1 23 Premature rupture 
of membranes  + 
Premature labor 
and delivery
20 mg/d + Fine 49 35 Cesarean 2,510 -
7 SMA (kidney) vascular 
> 1/320 glomerular 
- tubular - and SMA 
(stomach) > 1/320
1 28 Severe fetal growth 
restriction
20 mg/d - Average 22 36.9 Forceps 1,910 Perineal 
hematoma
8 Negative antibodies 1 25 - 20 mg/d + Eradicated 55 38 Vaginal 2,440 Perineal 
hematoma 
9 Negative antibodies 1 30 Fetal growth 
restriction + 
reduction of AF
20 mg/d - Average 51 33.4 Cesarean 1,580 -
2 31 Fetal growth 
restriction  + 
oligohydramnios
20 mg/d - Average 98 36.6 Cesarean 2,110 -
10 ALC-1 1/160 1 20 Pre-eclampsia 7,5 mg/d - Eradicated 80 35.7 Cesarean 1,760 -
SMA, anti-smooth muscle antibody, vascular, glomerular and tubular - kidney and liver; ALKM-1, antimicrosomal antibody, liver and kidney; ALC-1, anti-liver citosol antibody; AF, amniotic fluid. 
aPlatelet count at delivery before receiving platelet aphaeresis as needed.
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Gestational age was calculated from the date of the last 
menstrual period (DLM), when it was compatible with the 
gestational age estimated by the ultrasonography, performed 
up to the 20th week of gestation. In cases in which agreement 
was not observed, the gestational age was calculated through 
data of the first ultrasonography. The weight at birth in 
grams, weighed at the delivery room, was compared to the 
normality curve by Alexander et al.,4 and the results were 
classified as follows: small for the gestational age, weight at 
birth lower than the 10th percentile of the corresponding rank; 
adequate, between the 10th and 90th percentile; and large, 
above the 90th percentile.
Medcalc (v. 11.5.1.0) was used for analyzing the results. 
The categorical variables were descriptively analyzed by 
calculating relative and absolute frequencies. For analyzing 
continuous variables, the results were expressed as averages, 
medians, standard deviations, minimum values, and 
maximum values. 
Results
The present study followed up 13 pregnancies in ten patients 
with autoimmune hepatitis. One case evolved to miscarriage 
in the first trimester, diagnosed with anembryonic gestation, 
and was not included in the analysis. Maternal features 
and clinical data of the pregnant women with autoimmune 
hepatitis and thrombocytopenia who reached the third 
trimester are described on Table 1. 
Half of the cases occurred in nulliparous patients. 
According to the autoantibodies profile, seven gestations 
(58%) had type I autoimmune hepatitis, two gestations (17%) 
had type II, and three gestations (25%) had cryptogenic 
chronic hepatitis (titers of undetectable auto-antibodies). 
Portal hypertension was characterized in 11 gestations (92%) 
by the presence of esophageal varices in pregnancy (which 
in some instances had been eradicated) detected by high 
digestive endoscopy.
In six pregnancies (50%), thrombocytopenia was 
characterized as severe in some moment of pregnancy. 
Regarding the serological profile in prenatal care, all pregnant 
women had negative serology to human immunodeficiency 
virus (HIV), syphilis, and hepatitis B and C. No gestation 
presented infection by toxoplasmosis or rubella. 
The description of cases with the antibodies profile and 
obstetrical complications is presented on Table 2. Five 
patients had hepatic biopsy previous to pregnancy, and all 
of them had confirmed cirrhosis, in different degrees of 
activity. The clinical treatment adopted in pregnancy was 
prednisone in 11 cases (92%), for controlling the base disease. 
In patients using azathioprine, the medication was stopped 
in the first trimester, when pregnancy was diagnosed. At the 
time of delivery, severe thrombocytopenia was featured in 
four cases (33%), and complications in childbirth occurred in 
three cases (25%). The proportion of newborn infants small 
for the gestational age was 67%; there was no maternal or 
neonatal mortality.
 Table 3 shows the laboratory follow-up evolution of the 
main parameters in pre-gestational, gestational, and post-
childbirth periods. A reduction of red blood cell parameters 
during the pregnancy was observed, followed by a return to 
pre-gestation levels in the postpartum period. 
Discussion
Autoimmune hepatitis is associated with reduction of 
women’s fertility; however, the adequate control of disease 
increases the number of pregnancies in women bearing such 
disorder.5 Some studies point to the greater risk for fetal 
loss in these patients, mainly before the 20th gestational 
week. Schramm et al. reported 14.3% miscarriage in their 
study with 42 gestations, and Heneghan et al. reported 24% 
miscarriage in 35 gestations.6,7 In the largest review of cases 
on this topic, Candia et al. reported termination of pregnancy 
in 19% of 101 gestations, besides a perinatal mortality rate 
of 4%.8 In the present study, only one gestation evolved to 
such outcome in the first gestational trimester. However, the 
present study mainly focused on analyzing the management 
of pre-natal follow-up and of delivery in cases complicated 
by thrombocytopenia.
Table 3 – Gestation laboratory profile in patients with autoimmune hepatitis complicated by moderate or severe 
thrombocytopenia (n = 12). 
Pre-gestational
(n = 10)
1st trimester  
2nd trimester
(n = 11)
3rd trimester
(n = 12)
Delivery
(n = 12)
Puerperium
(n = 11)
Hemoglobin (g/dL) 13.05 (10.9-15.1) 11.5 (10.6-14.1) 12.35 (11.3-15.1) 11.45 (7.4-13.4) 12.1 (8.2-15.3)
Haematocrit (g/dL) 38.5 (31.8-44.5) 34.2 (31.4-41.4) 35.7 (32.7-45.8) 33.95 (23.4-40.8) 36.8 (28.2-45.1)
Platelets (n/mm3) 79.5 (44-97) 58 (29-101) 59 (31-97) 66 (22-111) 62 (43-106)
AST (U/L) 24.5 (16-56) 22 (16-44) 20.5 (13-45) 24 (13-94) 33 (25-67)
ALT (U/L) 22 (15-79) 17 (11-38) 15 (11-33) 16 (7-44) 24 (14-205)
GGT (U/L) 51.5 (22-208) 38 (15-192) 23 (11-124) 87 (11-181) 71 (23-291)
FA (U/L) 69.5 (24-123) 51 (29-145) 76.5 (33-138) 105 (49-195) 92 (67-265)
Data expressed as median (minimum – maximum). AST, aspartate aminotransferase; ALT, alanine transaminase; GGT, gamma-
glutamyltransferase; AF, alkaline phophatase. 
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In spite of the common association with other autoimmune 
disorders (celiac disease, ulcerative rectocolitis, and thyroid 
diseases),9 in the present study, no patient presented clinical 
or laboratory manifestation of this type of pathology.
According to the autoantibodies profile, autoimmune 
hepatitis can be divided into two main groups, type I and 
type II. Gleeson et al. stated that type I corresponds to 75% 
of cases in the general population and that, in some centers, 
there is a prevalence of 10% to 25% of patients with titers 
of undetectable or very low autoantibodies. In the present 
study, three cases were of this category, known as cryptogenic 
chronic hepatitis.4  
Terrabuio et al. demonstrated the safety of using prednisone 
and other immunosuppressants, such as azathioprine, 
for controlling autoimmune hepatitis in gestation.10 The 
modifications pregnancy causes in the disease are not well-
known. Autoimmune hepatitis frequently tends to be less 
aggressive during the pregnancy.11 There are, however, reports 
on acute exacerbation with acute hepatic failure during the 
gestational period.1 Werner et al. report exacerbation in 
10.5% of 63 pregnant women bearing autoimmune hepatitis 
using multiple immunosuppressants prescriptions.12 In the 
present study, azathioprine (when used) was stopped in 
the first gestational trimester, and the prednisone dose was 
adjusted to better control the disease. Besides, the laboratory 
dosages of hepatic enzymes presented a tendency of dropping 
during gestation, and of returning to the basal levels or 
rising during puerperium. In this study, no cases presented 
symptoms of acute exacerbation during pregnancy, and the 
use of prednisone was not responsible for any type of fetal or 
maternal involvement.
In the present study, cirrhosis was identified in varied 
degrees of activity on hepatic biopsies previous to gestation. 
Lohse et al. demonstrated that even though asymptomatic, 
early autoimmune hepatitis impairs the hepatic architecture 
in up to 33% of cases.1 Taking into account that all of pregnant 
women followed-up in this study presented a definite 
diagnosis for autoimmune hepatitis, and also considering 
the presence of portal hypertension in most of cases, it is 
possible to conclude that hepatic involvement was relevant, 
and must have concurred with a given degree of splenomegaly 
and greater platelet retention. These features confer more 
severity to cases studied regarding platelet count, requiring 
more attention and planning by the obstetrician regarding the 
time of delivery. Delivery should be scheduled with a blood 
and platelet reserve in case of emergency situations. It is 
recommended to avoid instrumentalised delivery in cases of 
severe thrombocytopenia. However, obstetrical indications 
for reducing the expulsive period are frequently prevalent in 
childbirth assistance. In the case (case 7) in which perineal 
hematoma was observed, forceps was indicated by prolonged 
expulsive period in a fetus presenting growth restriction. 
In the two cases presenting perineal hematoma, it was not 
necessary to perform a surgical drain, with improvement by 
local treatment.
Pregnant women with portal hypertension present a risk 
for bleeding of esophageal varices of around 20% to 45% 
in the third trimester. As it is quite difficult to predict the 
occurrence of high digestive hemorrhage during the delivery, 
some criteria are used for estimating such a possibility. 
The greater caliber of veins may indicate risk for bleeding. 
There are, however, some direct parameters, such as vein 
pressure and the presence of bleeding points; these data 
are obtained by high digestive endoscopy.13 In the present 
study, only information on the caliber of varices was used, 
and cesarean surgery was indicated for pregnant women 
with esophageal varices of medium/large caliber. The use 
of propanolol in a daily dose of 80 mg was also indicated. 
When the varices were non-existent or thin, and there 
were no other contraindications, the preferential method of 
delivery was vaginal. Fevery et al. postulate that in some cases 
vasoactive drugs, such as propranolol and spironolactone, can 
be administered for bleeding prophylaxis during the delivery, 
in the Valsalva maneuver.14 In the present study, no patient 
presented a clinical picture of high digestive hemorrhage 
during gestation or delivery.  
The clinical management of a patient during labor and 
delivery is complex, as bleeding is expected at the time of 
delivery. In severe thrombocytopenia with a platelet level lower 
than 50,000/mm3, neuroaxis block is routinely contraindicated; 
when a cesarean section is necessary, general anesthesia is 
usually indicated. Platelet replacement in the intra-operative 
period, when needed, can be performed by aphaeresis platelet 
transfusion. In the assistance to vaginal delivery, generally, 
the indication is for local anesthesia by pudendum nerve 
block. Moderate or severe thrombocytopenia restrict the use 
of peridural analgesia. In the present study, cesarean surgery 
was performed in seven gestations, and general anesthesia 
was the option in four of those cases (57%); in the five vaginal 
deliveries (42% of total), pudendum nerve block was used in 
three cases. The proportion of cesarean surgeries (58%) in 
the present study was similar to that reported in this service 
(56.5%) which assists high-risk pregnancies.15 
As to the complications directly related to childbirth, two 
cases evolved to perineal hematoma after vaginal delivery, and 
in both draining procedures were not needed, with resolution 
by local treatment. This type of complication is expected in 
thrombocytopenia cases, in management of delivery, and for 
this reason it is important to perform rigorous homeostasis 
and perineal review after the procedure. The same approach 
is recommended for cesarean surgery; however, as it is a 
large surgical procedure, the replacement of platelets may 
sometimes be necessary.
Schramm et al. describe premature birth rates from 6% to 
17% in patients with autoimmune hepatitis;6 Westbrook et al., 
in a recent study covering 81 gestations, describe prematurity 
rates of 20%.16 In the present study, there were five cases (42%) 
in which the childbirth occurred before the 37th week. The high 
rate of premature gestations can be explained by the associated 
comorbidities, especially by fetal growth restriction. Even 
though two thirds of newborn infants presented small size for 
the gestational age, none presented any type of malformation, 
despite the severe pathology and the prescribed treatment. In 
pregnancies with thrombocytopenia, the surveillance of fetal 
well-being is essential, as well as monitoring of fetus growth 
during the prenatal care.17
The present study has as a limitation the reduced sample 
size, which is explained by the greater severity of autoimmune 
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hepatitis complicating the pregnancy. The severity of cases 
makes it difficult to standardize clinical and surgical conduct, 
especially in delivery, which is subject to unpredictable 
complications. 
Conclusion
Autoimmune hepatitis associated with severe or moderate 
thrombocytopenia in pregnancy makes prenatal management 
and the assistance to delivery difficult. However, the disease 
tends to be milder during the gestation, which facilitates 
clinical treatment and in many cases allows for monotherapy. 
Treatment with prednisone appears to be sufficient for 
controlling the disease, but immediately after the end of 
pregnancy, it is relevant to pay careful attention to the clinical 
and laboratory follow-up for early detection in case of acute 
exacerbation of the disease. The bleeding complications in 
thrombocytopenic patients with autoimmune hepatitis are 
high, but with the appropriate healthcare and attention, they 
may be controllable. The association of two severe pathologies 
appears to increase the risk of prematurity and fetal growth 
restriction, alerting of the need to focus on specialized prenatal 
care, for better surveillance of fetal well-being.
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